ClinicalTrials.gg
RecruitingNCT01209000NEPTUNEUpdated Nov 10, 2026

Nephrotic Syndrome Study Network

An observational study in Minimal Change Disease (MCD), Membranous Nephropathy and Glomerulosclerosis, Focal Segmental, sponsored by University of Michigan. Recruiting at 44 sites in 2 countries. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Michigan · Observational

How we know

From the registry’s dates

  • Started Apr 2010; still recruiting 16 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
Up to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Nephrosis, Lipoid with a site in United States — 12 open to participants now, 13 under way, none of them phase 3. Nephrosis, Lipoid · United States.

Started
2010
the only one that year
Observational
7 of 25
4 open now
Primary completion
2030-12
later than 8 of 12 live
Registered
4th of 25
by date
Lead sponsor
5 of 25
University of Michigan

Among the 25 studies in Nephrosis, Lipoid with a site in United States, this one is the only one that started in 2010, is one of 7 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 4th registered.

Nephrosis, Lipoid

76 studies on the registry are indexed under Nephrosis, Lipoid; 33 are open to participants now.

Browse Nephrosis, Lipoid studies →

Open to participants now

12 of the 25 studies in Nephrosis, Lipoid with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Nephrosis, Lipoid studies recruiting now, 10 (40%) set no upper age limit and 10 (40%) stop at 75 or younger; 17 take children under 18; none take healthy volunteers.

This study: Up to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Nephrosis, Lipoid with a site in United States, or all of them as a file.
02

Study summary

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients.

In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium.

Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.

Read the detailed description

Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately 12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children. Treatment strategies for Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD) and Membranous Nephropathy (MN), the major causes of NS, include high dose prolonged steroid therapy, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil and other immunosuppressive agents, which all carry significant side effects. Failure to obtain remission using the current treatment approaches frequently results in progression to ESRD with its associated costs, morbidities, and mortality. In the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, half of the pediatric patients with Steroid Resistant Nephrotic Syndrome required renal replacement therapy within two years of being enrolled in the disease registry. FSGS also has a high recurrence rate following kidney transplantation (30-40%) and is the most common recurrent disease leading to allograft loss.

The prevailing classification of Nephrotic Syndrome categorizes patients into FSGS, MCD, and MN, if in the absence of other underlying causes, glomerular histology shows a specific histological pattern. This classification does not adequately predict the heterogeneous natural history of patients with FSGS, MCD, and MN. Major advances in understanding the pathogenesis of FSGS and MCD have come over the last ten years from the identification of several mutated genes responsible for causing Steroid Resistant Nephrotic Syndrome (SRNS) presenting with FSGS or MCD histopathology in humans and model organisms. These functionally distinct genetic disorders can present with indistinguishable FSGS lesions on histology confirming the presence of heterogeneous pathogenic mechanisms under the current histological diagnoses.

The limited understanding of FSGS, MCD, and MN biology in humans has necessitated a descriptive classification system in which heterogeneous disorders are grouped together. This invariably consigns these heterogeneous patients to the same therapeutic approaches, which use blunt immunosuppressive drugs that lack a clear biological basis, are often not beneficial, and are complicated by significant toxicity. The foregoing shortcomings make a strong case that concerted and innovative investigational strategies combining basic science, translational, and clinical methods should be employed to study FSGS, MCD, and MN. It is for these reasons that the Nephrotic Syndrome Study Network is established to conduct clinical and translational research in patients with FSGS/MCD and MN.

03

Conditions studied

  • Minimal Change Disease (MCD)
  • Membranous Nephropathy
  • Glomerulosclerosis, Focal Segmental

Keywords

  • Focal and Segmental Glomerulosclerosis
  • Focal & Segmental Glomerulosclerosis
  • Focal Segmental Glomerulosclerosis
  • FSGS
  • Minimal change disease
  • MCD
  • Membranous Nephropathy
  • MN
  • Nephrotic Syndrome
  • Neph Syndrome
  • NEPTUNE
  • NephCure
  • Halpin
04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or proteinuric renal disease or pediatric participants not previously biopsied, who present for patient care at participating clinical centers will be eligible for Cohort A (biopsy cohort) study population targeted for enrollment into the NEPTUNE study.

To establish a cohort of pediatric participants with incident nephrotic syndrome, Cohort B, a non-biopsy cohort has been initiated for Protocol V4.0. This population, \<19 years of age, presenting for nephrotic syndrome and less than 30 days of immunosuppression therapy exposure, will also be targeted for enrollment into the cNEPTUNE study.

Potential participants willing to receive their initial care and subsequent follow-up study visits at one of these sites are welcome to participate.

Eligibility criteria

Cohort A ( cohort) Inclusion Criteria:

Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:

  • Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.
  • Scheduled renal biopsy

Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:

  • Age \<19 years of age
  • Initial presentation with \<30 days therapy
  • Proteinuria/nephrotic

    • UA>2+ and edema OR
    • UA>2+ and serum albumin \<3 OR
    • UPC > 2g/g and serum albumin \<3

Exclusion Criteria (Cohort A\&B):

  • Prior solid organ transplant
  • A clinical diagnosis of glomerulopathy without diagnostic renal biopsy
  • Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)
  • Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)
  • Known systemic disease diagnosis at time of enrollment with a less than 6 months
  • Unwillingness or inability to give a comprehensive
  • Unwillingness to comply with study procedures and visit schedule
  • Institutionalized individuals (e.g., prisoners)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • FSGS/MCD Cohort (Cohort A)

    Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD. Eligible participants must be scheduled for a clinically indicated renal biopsy.

    Procedure: Kidney Biopsy

  • MN Cohort (Cohort A)

    Membranous Nephropathy (MN) Cohort Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN. Eligible participants must be scheduled for a clinically indicated renal biopsy.

    Procedure: Kidney Biopsy

  • Other glomerulopathies cohort

    Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group. Eligible participants must be scheduled for a clinically indicated renal biopsy.

    Procedure: Kidney Biopsy

  • cNEPTUNE (Cohort B)

    Participants \< 19 years of age, with \< 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.

Interventions

  • ProcedureKidney Biopsy

    Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

06

What researchers measure

Primary outcomes

  1. Event rate of change in urinary protein excretion and renal function.

    Defined as remission, partial remission and non-remission

    Time frame: 60 months

  2. Rate of change in renal function.

    Defined as: 1. 25 mls/min/1.73m2 reduction in follow-up estimated GFR (using the 4-variable MDRD equation for ages ≥18 years and modified Schwartz for ages \<18 years) compared to baseline estimated GFR 2. 50% decline in follow-up estimated GFR compared to baseline measurement 3. End stage renal disease defined as estimated GFR ≤10cc/min, initiation of maintenance dialysis or preemptive kidney transplantation.

    Time frame: 60 months

Secondary outcomes

  1. Quality of Life:

    Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals as stipulated in the visit calendar using the SF-36, PedsQL and the Patient Reported Outcome Measurement Information System (PROMIS) (in the age-appropriate groups).

    Time frame: 60 months

  2. Malignancies

    Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment in NEPTUNE

    Time frame: 60 months

  3. Infections, Serious and Systemic

    Infections including one of the following: 1. Documented diagnosis of infection of the skin or subcutaneous tissue (e.g. cellulitis), vascular system, peritoneum, or any vital organ requiring the use of parenteral antibiotics and/or oral antibiotics alone or in combination for a treatment interval of ≥72 hours. 2. Hospitalization for treatment of infection

    Time frame: 60 months

  4. Thromboembolic Events

    Documented diagnosis of one of the following: 1. Embolic cerebrovascular accident 2. Deep venous thrombosis 3. Renal vein thrombosis or 4. Pulmonary embolus

    Time frame: 60 months

  5. Hospitalization

    Documented hospital admission, including observation for ≥24 hours.

    Time frame: 60 months

  6. Emergency Department/ Observation Unit Visit

    Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours.

    Time frame: 60 months

  7. Acute Kidney Injury

    Documented diagnosis of acute kidney injury as defined by the AKIN (Mehta et al., Critical Care 2007, 11:R31) and/or renal failure requiring renal replacement therapy \<3 months.

    Time frame: 60 months

  8. Death

    1. Documentation of death that is secondary to infection or sepsis. 2. Cardiovascular/Cerebrovascular-related Death: Sudden death; Myocardial infarction; Congestive heart failure; Primary intractable serious arrhythmia; Peripheral vascular disease; Ischemic cerebrovascular accident; Hemorrhagic cerebrovascular accident; Thromboembolic event 3. Documentation of death secondary to cancer 4. Other Death: Documentation of death that does not fall into the above categories.

    Time frame: 60 months

  9. New Onset Diabetes

    Diagnosis of diabetes as indicated by 1 or more of the following not present at NEPTUNE Enrollment: 1. Documented diagnosis of diabetes in medical record 2. Casual (non-fasting) blood glucose \> 200 mg/dL c) Fasting blood glucose \> 126 mg/dL d) 2 hour glucose \> 200 after oral glucose tolerance test e) chronic use (\>6 mos) hypoglycemic therapy outside of pregnancy f) Hemogloblin A1C \>= 6.5%

    Time frame: 60 months

07

Study locations

33 of 44 sites recruiting
  • University of Southern California-Children's Hospital
    Los Angeles, California 90227, United States
    Recruiting
    • Sharon Tang, BSN · Contactshatang@chla.usc.edu · 323-361-7299
    • Kevin Lemley, MD, PhD · Principal investigator
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
    Recruiting
    • Kshama Mehta, PhD · Contactkrmehta@stanford.edu · 650-736-1822
    • Richard Lafayette, MD · Principal investigator
  • University of California San Francisco Benioff Children's Hospitals
    San Francisco, California 94158, United States
    Not yet recruiting
  • Lundquist Biomedical Research Institute at Harbor UCLA Medical Center
    Torrance, California 90502, United States
    Recruiting
    • Janine LaPage · Contactjlapage@labiomed.org · 310-222-4104
    • Sharon Adler, MD · Principal investigator
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • University of Colorado Anschutz School of Medicine
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
    Recruiting
    • Carlos Bidot · Contactcbidot2@miami.edu · 305-243-8973
    • Alessia Fornoni, MD. PhD · Principal investigator
  • Emory University and Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
    Recruiting
    • Emily Yun · Contactemily.yun@emory.edu · 404-712-9998
    • Laurence Greenbaum, MD, PhD · Principal investigator
  • John Stroger Cook County Hospital
    Chicago, Illinois 60680, United States
    Recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • Catherine Creed · Contactccreed@kumc.edu
    • Ellen McCarthy, MD · Principal investigator
  • Johns Hopkins Medical Institute
    Baltimore, Maryland 21287, United States
    Recruiting
    • Sara Boynton · Contactsboynto3@jhmi.edu · 443-287-9051
    • Alicia Neu, MD · Principal investigator
    • Michael Choi, MD · Sub investigator
  • Kidney Disease Section, NIDDK, NIH
    Bethesda, Maryland 20892, United States
    Completed

    Not enrolling at this site — choose another above.

  • CS Mott Children's Hospital, University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Hailey Desmond, MS · Contactheturner@umich.edu · 734-232-4851
    • Debbie Gipson, MD, MS · Sub investigator
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Chrysta C. Lienczewski, BS - adult · Contactboridley@med.umich.edu · 734-615-5021
    • Amanda Williams, BS - adult · Contactamwi@umich.edu · 734-615-5017
    • Matthias Kretzler, MD · Principal investigator
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Completed

    Not enrolling at this site — choose another above.

  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
    • Kelsey Markus · Contactkemarkus@cmh.edu
    • Tarak Srivastava, MD · Principal investigator
  • Washington University - St Louis
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • Cohen Children's Hospital
    New Hyde Park, New York 11040, United States
    Recruiting
    • Suzanne Vento, BSN · Contactsvento@northwell.edu · 718-470-3499
    • Christine Sethna, MD · Principal investigator
  • New York University Medical Center
    New York, New York 10010, United States
    Recruiting
  • Bellevue Hospital
    New York, New York 10016, United States
    Recruiting
    • Frank Modersitzki, MPH · ContactFrank.Modersitzki@va.gov · 212-686-7500
    • Laura Barisoni, MD · Principal investigator
    • Olga Zhadnova, MD · Sub investigator
  • New York University Veterans Administration
    New York, New York 10016, United States
    Recruiting
    • Frank Modersitzki, MPH · ContactFrank.Modersitzki@va.gov · 212-686-7500
    • Laura Barisoni, MD · Principal investigator
    • Olga Zhadnova, MD · Sub investigator
  • Columbia University Medical Center
    New York, New York 10032, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York 11040, United States
    Recruiting
    • Patti Flynn, RN · Contactpflynn@montefiore.org · 718-655-1120
    • Frederick Kaskel, MD · Principal investigator
    • Robert Woroniecki, MD · Sub investigator
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
    Recruiting
    • Anne Froment · ContactAnne_Froment@med.unc.edu · 919-923-1382
    • Fernanda Ochoa · Contactferochoa@email.unc.edu
    • Patrick H. Nachman, MD · Principal investigator
    • Susan L. Hogan, PhD, MPH · Sub investigator
    • Keisha Gibson, MD · Sub investigator
  • Atrium Health Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
    Recruiting
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Hospital Rainbow Babies & Children's Hospital
    Cleveland, Ohio 44106, United States
    Completed

    Not enrolling at this site — choose another above.

  • MetroHealth Hospital at Case Western Medical Center
    Cleveland, Ohio 44109, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Stefanie Larson · Contactlarsons2@ccf.org
    • Villarreal · Contact
    • Katherine Dell, MD · Sub investigator
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
    Recruiting
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Temple University
    Philadelphia, Pennsylvania 19140, United States
    Recruiting
    • Zoe Pfeffer, BS · Contactzoe.pfeffer@tuhs.temple.edu · 215-707-4712
    • Crystal Gadegbeku, MD · Principal investigator
    • Iris Lee, MD · Principal investigator
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • David Selewski, MD, MS · Principal investigator
  • University of Texas-Southwestern
    Dallas, Texas 75390, United States
    Recruiting
  • Texas Children's Hospital - Baylor College of Medicine
    Houston, Texas 77030, United States
    Recruiting
  • Seattle Children's Hospital
    Seattle, Washington 98145, United States
    Recruiting
  • University of Washington
    Seattle, Washington 98195, United States
    Recruiting
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
    Recruiting
  • York Central Hospital
    Richmond Hill, Ontario L4C 4Z3, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Scarborough Hospital
    Scarborough Village, Ontario M1H 3G4, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Credit Valley Hospital
    Toronto, Ontario L5M 2N1, Canada
    Recruiting
    • Martin Romano, MD · Contactmartin.romano@thp.ca · 416-340-3514
    • Phillip Boll, MD · Sub investigator
  • Sunnybrook Hospital
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
  • University Health Network
    Toronto, Ontario M5G2C4, Canada
    Recruiting
08

References and documents

Publications

  • Wang CS, Troost JP, Wang Y, Greenbaum LA, Gibson K, Trachtman H, Srivastava T, Reidy K, Kaskel F, Sethna CB, Meyers K, Dell KM, Tran CL, Hingorani S, Lemley KV, Lin JJ, Gipson DS. Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. Pediatr Nephrol. 2022 Jul;37(7):1585-1595. doi: 10.1007/s00467-021-05176-8. Epub 2021 Nov 18. PubMed 34796395 ↗
  • Solagna F, Tezze C, Lindenmeyer MT, Lu S, Wu G, Liu S, Zhao Y, Mitchell R, Meyer C, Omairi S, Kilic T, Paolini A, Ritvos O, Pasternack A, Matsakas A, Kylies D, Wiesch JSZ, Turner JE, Wanner N, Nair V, Eichinger F, Menon R, Martin IV, Klinkhammer BM, Hoxha E, Cohen CD, Tharaux PL, Boor P, Ostendorf T, Kretzler M, Sandri M, Kretz O, Puelles VG, Patel K, Huber TB. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs. J Clin Invest. 2021 Jun 1;131(11):e135821. doi: 10.1172/JCI135821. PubMed 34060483 ↗
  • Kang H, Kim DR, Jung YH, Baek CW, Park YH, In Oh J, Kim WJ, Choi GJ. Pre-warming the Streamlined Liner of the Pharynx Airway (SLIPA) improves fitting to the laryngeal structure: a randomized, double-blind study. BMC Anesthesiol. 2015 Nov 20;15:167. doi: 10.1186/s12871-015-0151-4. PubMed 26589142 ↗
  • Hogan MC, Lieske JC, Lienczewski CC, Nesbitt LL, Wickman LT, Heyer CM, Harris PC, Ward CJ, Sundsbak JL, Manganelli L, Ju W, Kopp JB, Nelson PJ, Adler SG, Reich HN, Holzmann LB, Kretzler M, Bitzer M. Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrol. 2015 Nov 17;16:190. doi: 10.1186/s12882-015-0185-3. PubMed 26577187 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2010 (actual). Primary completion is estimated for Dec 2030, 248 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2010
First posted
Sep 24, 2010
StartActual
Apr 2010
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01209000
Responsible party
Matthias Kretzler (Professor, University of Michigan) — Principal investigator
First posted
Sep 24, 2010
Start date
Apr 2010
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Chrysta C. Lienczewski, BS
Contact
NEPTUNE-Study@umich.edu
734-615-5021
Amanda Williams, BS
Contact
NEPTUNE-Study@umich.edu
734-615-5017
Matthias Kretzler, MD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion